GW Pharmaceuticals is the first company to bring a cannabis plant-based drug to market to treat rare forms of epilepsy. Epidiolex ® (cannabidiol or CBD) was cleared by the FDA in June 2018 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. The drug received a Fast Track designation by the FDA due to its great potential shown in successful trials with children and because at the time there were no other drugs to treat Dravet syndrome effectively. CBD has also been rescheduled as a Schedule V drug.
https://www.federalregister.gov/documents/2018/09/28/2018-21121/schedules-of-controlled-substances-placement-in-schedule-v-of-certain-fda-approved-drugs-containing
Cannabis is now legally being used to treat a wide variety of medical conditions, including chronic pain, alcoholism, anxiety, nausea (from chemotherapy) and epilepsy.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Cannabis is now legally being used to treat a wide variety of medical conditions, including chronic pain, alcoholism, anxiety, nausea (from chemotherapy) and epilepsy.